High dose therapy/ASCT consolidated with rituximab and or alpha interferon immunotherapy for relapsed follicular lymphoma prolongs progression free survival and achieves durable molecular remissions.

被引：0
|
作者：
Buckstein, RJ
Mangel, J
Imrie, K
Spaner, D
Crump, M
Pennell, N
Boudreau, A
Reis, M
Robinson, J
Romans, R
Richardson, P
Nagy, T
Berinstein, N
机构：
[1] Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Adv Therapeut Program, Toronto, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2547
引用
收藏
页码：647A / 648A
页数：2
相关论文
共 23 条
  • [1] High dose therapy/ASCT consolidated by rituximab and or interferon immunotherapy for relapsed follicular lymphoma achieves durable molecular remissions and improved progression free survival.
    Buckstein, R
    Mangel, JJ
    Imrie, K
    Spaner, D
    Piliotis, G
    Crump, M
    Pennell, N
    Boudreau, A
    Reis, M
    Robinson, J
    Romans, R
    Nagy, T
    Richardson, P
    Berinstein, N
    BLOOD, 2003, 102 (11) : 491B - 491B
  • [2] High dose therapy/ASCT with rituximab for in-vivo purging and post-ASCT consolidation in relapsed follicular lymphomas achieves prolonged clinical and molecular remissions.
    Woods, AC
    Buckstein, R
    Mangel, J
    Imrie, K
    Spaner, D
    Crump, M
    Pennell, N
    Boudreau, A
    Reis, M
    Berinstein, N
    BLOOD, 2004, 104 (11) : 262A - 262A
  • [3] The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions
    Bhella, Sita
    Berinstein, Neil L.
    Pennell, Nancy
    Cheung, Matthew
    Imrie, Kevin R.
    Miliken, Violet
    Reis, Marciano D.
    Chesney, Alden
    Good, David
    Hicks, Lisa
    Piliotis, Eugenia
    Crump, Michael
    Buckstein, Rena
    BLOOD, 2010, 116 (21) : 583 - 583
  • [4] Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α
    Smyth, Liam
    Buckstein, Rena
    Nancy, Pennell
    Weerasinghe, Rashmi
    Cheung, Matthew
    Piliotis, Eugenia
    Imrie, Kevin
    Spaner, David
    Reis, Marciano D.
    Chodirker, Lisa
    Ghorab, Zeina
    Ruth, Violet
    Milliken, Nancy
    Boudreau, Angela
    Berinstein, Neil
    BLOOD, 2017, 130
  • [5] Prolonged clinical and molecular remissions following high-dose therapy/autologous stem cell transplantation (HDT/ASCT) and rituximab and interferon-alpha maintenance for relapsed high-risk follicular lymphoma.
    Cheung, Matthew C.
    Berinstein, Neil L.
    Pennell, Nancy
    Hicks, Lisa K.
    Imrie, Kevin R.
    Piliotis, Eugenia
    Milliken, Violet
    Reis, Marciano
    Buckstein, Rena
    BLOOD, 2007, 110 (11) : 565A - 565A
  • [6] Durability of molecular remissions in patients receiving high dose therapy and stem cell support with interferon maintenance for relapsed follicular lymphoma.
    Tompkins, KA
    Imrie, KR
    Buckstein, R
    Spaner, D
    Mangel, J
    Reis, M
    Perez-Ordonez, B
    Romans, R
    Pennell, N
    Robinson, J
    Hewitt, K
    Richardson, P
    Lima, A
    Pavlin, P
    Berinstein, NL
    BLOOD, 2001, 98 (11) : 400B - 400B
  • [7] Immunoglobulin recovery following high dose therapy,and post-ASCT rituximab for relapsed follicular Lymphoma(FL) and newly diagnosed mantle cell lymphoma (MCL) compared to standard dose chemotherapy +/- Rituximab®.
    Buckstein, RJ
    Mangel, J
    Imrie, KR
    Spaner, D
    Boudreau, A
    Crump, M
    Pao, J
    Foden, C
    Berinstein, N
    BLOOD, 2002, 100 (11) : 480B - 480B
  • [8] Alpha interferon can reinduce molecular remission in patients with molecular relapse after high dose therapy for follicular lymphoma.
    McQuaker, IG
    Haynes, AP
    Carter, GI
    Byrne, J
    Fletcher, J
    Davies, JM
    Bessell, EM
    Russell, NH
    BLOOD, 1997, 90 (10) : 4466 - 4466
  • [9] Long-Term Clinical and Molecular Remissions in Patients with Follicular Lymphoma (FL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
    Metzner, Bernd
    Rosien, Bernd
    Casper, Jochen
    Kohne, Claus-Henning
    Kraemer, Doris M.
    Mueller, Thomas H.
    Renzelmann, Andrea
    Thole, Ruth
    Pott, Christiane
    BLOOD, 2017, 130
  • [10] High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
    Schouten, HC
    Qian, W
    Kvaloy, S
    Porcellini, A
    Hagberg, H
    Johnsen, HE
    Doorduijn, JK
    Sydes, MR
    Kvalheim, G
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3918 - 3927
123